BIA
JANX icon

Bell Investment Advisors’s Janux Therapeutics JANX Stock Holding History

Bell Investment Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-138
Closed -$1.92K – 1867
2026
Q1 		$1.92K Buy
+138
New +$1.89K ﹤0.01% 1350

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Bell Investment Advisors's JANX Position: Q2 2026 in Review

Bell Investment Advisors sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 138 shares — an estimated $1.92K sold.

Bell Investment Advisors first reported a position in JANX in Q1 2026 and held it in 1 quarter. The position peaked at $1.92K in Q1 2026. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Bell Investment Advisors reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bell Investment Advisors sold 138 Janux Therapeutics shares in Q2 2026, an estimated $1.92K.
  • Bell Investment Advisors first reported a position in Janux Therapeutics in Q1 2026 and held it in 1 quarter.
  • Bell Investment Advisors's Janux Therapeutics position peaked at $1.92K in Q1 2026.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.